gvtcx

NHS National Generic Pharmaceuticals Wave 13

NHS England Published 21 Jun 2021 Contracts Finder

key details

Value£710,767,138
Statusactive
Category (CPV) 33600000
RegionEast Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber
Deadline26 Jul 2021
Contract start1 Feb 2022
Contract end31 May 2024
Procedureopen
SME suitableYes
OCIDocds-b5fd17-582c14ad-7a7d-400d-864c-5d539c4b1eae

description

Tender Close: 26th July 2021, 13:00.

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13

Offer reference number: CM/PHG/17/5532

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)

CESW: 1 March 2022 - 30 September 2023 (19 months)

LSNE: 1 March 2022 - 31 January 2023 (11 months)

NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals

All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products

CESW: 1 February 2022 - 30 September 2023 (20 months)

LSNE: 1 February 2022 - 31 May 2024 (28 months)

NWLN: 1 February 2022 - 31 January 2023 (12 months)

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
21 Jun 2021 Tender (tender) · 3a757f1b-d279-4a70-b99c-b077c5caa22b-445208

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.